BloodPAC’s Executive Director, Lauren Leiman, sat down with Epic Sciences to discuss the important work the organization is doing to build collaboration among oncology stakeholders to standardize liquid biopsies, improve cancer care and outcomes for patients. Listen here
The College of American Pathologists (CAP) continues to support and provide expert input on the BloodPAC Data Commons and recognizes the BloodPAC Consortium’s latest pre-analytical minimal technical data elements (MTDEs) as a best practice example of developing preanalytical factors “fit-for-use” for studies utilizing technologies profiling ctDNA in cancer patients. In addition to BloodPAC pre-analytical MTDEs, the CAP also encourages consulting the CAP Biorepository Accreditation Program (BAP) guidelines as well as those set forth in the National Cancer Institute’s Best Practices and by the International Society for Biological and Environmental Repositories to ensure that uniform practices are used in all BAP-accredited organizations. The CAP will monitor any changes proposed by the BloodPAC Consortium that may impact guidelines and best practices and reconsider this statement as appropriate.
This week’s news that the Securities and Exchange Commission charged Theranos and its CEO with fraud put the troubles of the company back into the spotlight. For those of us in the field of liquid biopsy, Theranos has cast a long and persistent shadow on what’s clearly one of the most promising areas in cancer care — using blood tests to improve detection, diagnosis, and treatment and, more broadly, advancing the reality of precision medicine in cancer.
NEW YORK (GenomeWeb) – After releasing its first public data on the standards that it has arrived at for sample annotation and submission, the Blood Profiling Atlas in Cancer Consortium (BloodPAC) is pushing forward with its effort to aggregate data from a wide range of liquid biopsy platforms.
On the One-Year Anniversary, Public Release of First Harmonized Datasets Will Open New Opportunities for Innovation and Collaboration
CHICAGO – Exactly one year after its establishment as an independent non-profit, The Blood Profiling Atlas in Cancer Consortium (BloodPAC) announced the public release and accessibility of an initial dataset. The dataset resides in the BloodPAC Data Commons and was developed to deepen the understanding of an individual patient’s cancer and accelerate the development of liquid biopsy technology to improve the outcomes of patients with cancer. Prior to establishing itself as an independent entity, BloodPAC was a collaborative commitment to the Cancer Moonshot initiative spearheaded by former Vice President, Joseph R. Biden, Jr.
Published in Clinical Pharmacology and Theraputics, April 12, 2017
The cancer community understands the value of blood profiling measurements in assessing and monitoring cancer. We describe an effort among academic, government, biotechnology, diagnostic, and pharmaceutical companies called the Blood Profiling Atlas in Cancer (BloodPAC) Project. BloodPAC will aggregate, make freely available, and harmonize for further analyses, raw datasets, relevant associated clinical data (e.g., clinical diagnosis, treatment history, and outcomes), and sample preparation and handling protocols to accelerate the development of blood profiling assays.
The Breast Cancer Research Foundation (BCRF) and the Prostate Cancer Foundation (PCF) announce their commitment to advancing the understanding of metastatic disease in patients through their support of the Blood Profiling Atlas in Cancer (Blood PAC). In alignment with Vice President Biden’s Cancer Moonshot initiative, the Blood PAC was formed in October 2016 to support the mission of making very direct progress towards patient benefit through research. Blood PAC is a public private partnership of now over twenty organizations that have pledged support by contributing liquid biopsy data, protocols, and expertise into an open data commons.
Thanks to remarkable scientific advances, we know that tumors shed a variety of signals into the blood, leaving behind small hints to help identify cancer type, location, and disease-stage. For this reason, researchers are especially interested in developing new ways to use this knowledge to transform how we detect and diagnose cancer, making it possible for a future wherein simple blood draws could help physicians and patients more accurately and successfully manage disease.